

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wolin *et al.* Confirmation No. 7188
Appl. No.: 09/815,597 Group Art Unit: 1642
Filed: March 23, 2001 Examiner: Sheela Jitendra Huff
For: METHODS OF THERAPY FOR NON-HODGKIN'S LYMPHOMA

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313



November 21, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 along with a copy of the non-patent literature documents in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

Respectfully submitted,

A handwritten signature in black ink that reads "Leslie T. Henry".

Leslie T. Henry
Registration No. 45,714

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EV 387073625 US
Date of Deposit November 21, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:
Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

A handwritten signature in black ink that reads "Nora C. Martinez".

Nora C. Martinez

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1 Application Number 09/815,597 Filing Date March 23, 2001 First Named Inventor Wolin Group Art Unit 1632 Examiner Name Sheela Jitendra Huff Attorney Docket Number PP01658.002 (035784/209107)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office ³ Number ⁴	Kind Code (if known) ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	47	ATKINS, M.B., "Interleukin-2: Clinical Applications," <i>Seminars in Oncology</i> , 2002, pp. 12-17, Vol. 29(3).	
	48	FEHNIGER, T.A., <i>et al.</i> , "Potential Mechanisms of Human Natural Killer Cell Expansion <i>In Vivo</i> During Low-Dose IL-2 Therapy," <i>The Journal of Clinical Investigation</i> , July 2000, pp. 117-124, Vol. 106(1).	
	49	MEROPOL, N.J., <i>et al.</i> , "Evaluation of Natural Killer Cell Expansion and Activation <i>In Vivo</i> with Daily Subcutaneous Low-Dose Interleukin-2 Plus Periodic Intermediate-Dose Pulsing," <i>Cancer Immunology and Immunotherapy</i> , 1998, pp. 318-326, Vol. 46.	
	50	THUMMALA, A.R., <i>et al.</i> , "A Phase I/II Study of Rituxan and Interleukin 2 (IL-2) in Patients with Low Grade or Mantle Cell Non-Hodgkins Lymphoma (NHL)-Preliminary Results," Database Biosis Online Accession No. PREV200200152443, page 250b, Abstract 4732; appearing in <i>Blood</i> , November 16, 2001, page 250b, Vol. 98, No. 11, Part 2.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2185005v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.